Share

In This Section

Home / Resource Library Search

Resource Library Search Filter

Filter By Resource Library: Format Type
Filter By Resource Library: Topic

Resource Library Search

"This article shows that poor early MRD response, in contrast to conventional ALL risk factors, is an excellent tool to identify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy."
Blood
"Initial imatinib-based therapy of Ph+ adult ALL is associated with lower early mortality and higher CR rate. In adults with Ph+ ALL, allogeneic SCT in first CR prolongs relapse-free survival and OS."
Blood
Authors report the results of molecular MRD monitoring based on IG/TR and/or BCR/ABL1 transcript as PCR markers and their predictive value in patients treated with imatinib in the EsPhALL study.
Haematologica
"Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms... Our study indicates that the BIOMED-2 multiplex PCR tubes provide a powerful strategy for clonality assessment in T-cell malignancies assisting the firm diagnosis of T-cell neoplasms."
Leukemia
This palm card provides a list of support services offered by LLS.
The Leukemia and Lymphoma Society (LLS)
This video series aims to answer questions that patients may have about lab and imaging tests.
The Leukemia and Lymphoma Society (LLS)
This worksheet can help you develop and guide your PDSA cycle.
Mountain-Pacific Quality Health
A complete list of LLS's financial assistance programs to help individuals with blood cancer. You can also call 877-557-2672 to reach LLS's Patient Financial Assistance Programs.
The Leukemia and Lymphoma Society (LLS)
Download or order free information booklets from LLS.
The Leukemia and Lymphoma Society (LLS)
"Next-generation sequencing (NGS) of immunoglobulin (IG) and T cell receptor (TR) rearrangements represents a modern alternative to classical RQ-PCR-based MRD detection."
Leukemia Stem Cells: Methods and Protocols
NCCN offers clinical guidelines to guide the treatment and care of patients with ALL.
National Comprehensive Cancer Network (NCCN)
This website is intended to provide helpful materials and information on MRD testing to support people with blood cancer and their families.
MRD Testing Collaborative
This study used the genomic breakpoint between BCR and ABL1 genes for the DNA-based monitoring of MRD in 48 patients with childhood ALL.
Blood
"Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standard-risk acute lymphoblastic leukemia (ALL) after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enrolled in the German Multicenter ALL (GMALL) trial by real-time quantitative polymerase chain reaction (PCR) of clonal immune gene rearrangements."
Blood
This handout provides an overview of MRD for individuals with blood cancer.
The Leukemia and Lymphoma Society (LLS)
"These guidelines provide evidence surrounding the clinical utility of MRD testing using multiparameter flow cytometry (MFC), next-generation sequencing (NGS), or polymerase chain reaction (PCR)-based methods in patients with ALL."
Cancer Care Ontario
"Early response to therapy is one of the most important prognostic factors in acute leukemia, which prompted authors to investigate whether or not early immunophenotypic assessment of MRD could also be a valuable tool for predicting relapse in adult patients with ALL. For that purpose, this study analyzed the level of MRD during the initial phase of treatment (induction phase) by multiparameter flow cytometry in a series of 102 adolescent (older than 14 years) and adult patients with ALL."
Blood
"Through a review of the literature and in house data, authors analyze the current status of MRD assessment in ALL to better understand how some of its limitations could be overcome by emerging molecular technologies. Authors highlight the future role of MRD monitoring in the context of personalized protocols, taking into account the genetic complexity in ALL."
Frontiers in Oncology
"MRD diagnostics has proven to be the strongest prognostic factor, allowing for risk group assignment into different treatment arms, ranging from significant treatment reduction to mild or strong intensification. Also in relapsed ALL patients and patients undergoing stem cell transplantation, MRD diagnostics is guiding treatment decisions."
Blood
"Current methods to diagnose MRD are through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry, polymerase chain reaction, real-time quantitative polymerase chain reaction, reverse transcription polymerase chain reaction or NGS."
International Journal of Molecular Sciences